- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01432652
The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery
Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance
Study Overview
Status
Conditions
Detailed Description
About 15% of the general population shows resistance to the antiplatelet effects of aspirin, due to genetic polymorphisms and other factors. This resistance is a cause of increased myocardial infarction and death in patients undergoing percutaneous coronary interventions. Aspirin resistance can be detected by whole blood impedance aggregometry using the Multiplate® analyzer. The population of patients undergoing vascular surgery is at particular risk of suffering myocardial infarction in the perioperative period because of the high prevalence of risk factors. Most of these patients are treated by aspirin, as a measure of primary or secondary prevention. In this study we aim to establish baseline aspirin efficacy, as measured by the Multiplate® analyzer, in this high-risk population and evaluate the changes in aspirin efficacy over the first five days of the postoperative period. It is our hypothesis that the state of chronic inflammation, accompanying severe, generalized atherosclerosis results in a higher incidence of aspirin resistance in this population. Also, the surgical trauma and postoperative thrombocytosis may reduce the efficacy of aspirin in the postoperative period, partially explaining the increased incidence of postoperative myocardial infarction in this population.
In whole blood impedance aggregometry, the electrical impedance of the blood sample is measured by placing two electrodes in the recipient. After the addition of a platelet activator, the impedance will increase as platelets accumulate on the electrodes surfaces. Several activators, testing the patency of different platelet receptors can be used.
In this study, blood will be drawn on the day of surgery, and daily until the fifth postoperative day. Arachidonic acid, ADP, TRAP-6 and collagen will be used as activators. The first specifically tests the platelets reactivity to thromboxane A2. Aspirin inhibits this pathway, and the increase in impedance should therefore be limited in patients treated by this drug. The three other tests will be performed to evaluate the evolution of overall platelet reactivity in the postoperative period.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- University of Lausanne Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient undergoing peripheral vascular or abdominal aorta surgery.
- Patient aged 18 years or older.
- Patient treated by aspirin.
Exclusion Criteria:
- Incapacity to understand and consent to study.
- Patient undergoing emergency surgery.
- Patient treated by a cox-inhibitor other than aspirin.
- Patient treated by omega-3-fatty acids.
- Patient treated by ADP or GPIIb/IIIa receptor inhibitor.
- Known coagulopathy, thrombopenia, thrombopathia or congenital or acquired thrombasthenia.
- Terminal renal insufficiency.
- Hepathic insufficiency.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
vascular surgery
Patients undergoing vascular surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 176/11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aspirin Resistance
-
University of PennsylvaniaBayer; National Institutes of Health (NIH)CompletedAspirin Resistance | Pharmacological Aspirin Non-responsiveness
-
Northwell HealthStaten Island University HospitalCompletedAspirin Resistance
-
Azienda Ospedaliera San Giovanni BattistaUnknown
-
University Hospital, LimogesCompletedAspirin ResistanceFrance
-
Ziv HospitalCompletedHypercholesterolemia | Aspirin ResistanceIsrael
-
Hamilton Health Sciences CorporationCompleted
-
Chinese University of Hong KongUnknownAspirin | MicrobiotaHong Kong
-
University of ZagrebCompletedCoronary Artery Disease | Aspirin ResistanceCroatia
-
Duke UniversityCompletedAspirin | Platelet Aggregation Inhibitors | Ticagrelor | RNAUnited States
-
BayerCompletedAspirin | Drug Safety | Effects, LongtermGermany